ClinicalTrials.gg
Active, not recruitingNCT06470308Updated Feb 9, 2026

Prescribing Outcomes of a GP-Targeted Deprescribing Educational Intervention: A Cluster Randomized Trial

An interventional study of Medication Reviews and Deprescribing in Medication Overuse, Deprescriptions and Polypharmacy, sponsored by University of Crete. Active, not recruiting at 1 site in Greece. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by University of Crete · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Polypharmacy is a common and growing public health concern across healthcare settings worldwide and is associated with an increased risk of inappropriate prescribing and adverse drug events. Deprescribing-defined as the supervised withdrawal of potentially inappropriate medications using structured tools and clinical judgment-has been proposed as a strategy to improve prescribing safety. In Greece, formal initiatives and evidence evaluating deprescribing interventions in primary care remain limited.

This study is a cluster randomized controlled trial evaluating the effect of an educational intervention for general practitioners (GPs) on prescribing safety in primary care. Participating GPs are randomized in an approximately 1:1 ratio to an intervention or control arm. GPs in the intervention arm receive structured education and training on medication review and deprescribing, including the use of validated deprescribing tools such as the Beers Criteria. GPs in the control arm provide usual care and do not receive any educational intervention.

Patients receiving care from participating GPs are recruited, and prescribing outcomes are assessed at the patient level. The primary outcome is change in prescription medications following the intervention, comparing patients cared for by GPs in the intervention arm versus those cared for by GPs in the control arm.

02

Conditions studied

  • Medication Overuse
  • Deprescriptions
  • Polypharmacy
  • Frailty Syndrome
03

In context

Prescription Drug Overuse

9 studies on the registry are indexed under Prescription Drug Overuse; none are open to participants now.

Browse Prescription Drug Overuse studies →

Lead sponsor

University of Crete is the lead sponsor of 23 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • community-dwelling patients
  • Age ≥ 65 years
  • Receive at least 5 medication ( polypharmacy )

Exclusion criteria

Exclusion Criteria:

  • hospitalized or patients living in nursing home
  • Incapable of giving written consent
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    An educational intervention and training in deprescribing algorithms and deprescribing tools ( Beers Criteria) will be provided to the general practitioners caring for the patients selected in the intervention arm.

    Other: Medication Reviews and Deprescribing

  • No intervention
    Control Arm

    No educational intervention will be provided to the general practitioners of the selected patients.

Interventions

  • OtherMedication Reviews and Deprescribing

    General Practitioners will be given training and education in deprescribing algorithms and the conduction of medication reviews with the use of validated deprescribing tools such as the Beers Criteria.

06

What researchers measure

Primary outcomes

  1. Potentially Inappropriate Medication

    Determine if there is reduction in potentially Inappropriate medication after a deprescribing education intervention

    Time frame: 1 years

  2. Number of medications

    Determine if there is reduction in number of medications after a deprescribing education intervention

    Time frame: 1 year

07

Study locations

1 site
  • Primary Care Facilities
    Heraklion, Heraklion, Crete 71303, Greece
08

References and documents

Individual participant data

Plan to share: No — All the data that will be collected, will be retained only during the period needed for the aims of this research. Technical and organizational measures will be taken in order to minimize potential loss, destruction or corruption of the data.After the completion of the thesis , all the data will be destroyed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Dec 2025, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jun 24, 2024
StartActual
Nov 18, 2024
Primary completionActual
Dec 30, 2025
CompletionEst.
Mar 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06470308
Lead sponsor
University of Crete
Responsible party
Alexandros Paraskevopoulos (MD , PhD Candidate, University of Crete) — Principal investigator
First posted
Jun 24, 2024
Start date
Nov 18, 2024
Primary completion
Dec 30, 2025
Completion
Mar 2026 (estimated)
Last update
Feb 9, 2026

Study contacts

Ioanna Tsiligianni, MD, PhD
study chair · Associate Professor in General Practice and Public Health, Department of Social Medicine, University of Crete

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion